<br>        Inclusion Criteria:<br><br>          -  Confirmed diagnosis of cystic fibrosis<br><br>          -  Male and female patients at least 6 years of age at the time of screening.<br><br>          -  Forced expiratory volume in one second (FEV1) at screening must be at least 25% and<br>             less than or equal to 75% of normal predicted values for age, sex, and height based on<br>             Knudson criteria.<br><br>          -  Pseudomonas aeruginosa, a type of bacteria, must be present in a sputum/deep-throat<br>             cough swab culture (or bronchoalveolar lavage [BAL]) within 6 months prior to<br>             screening and in the sputum/ deep-throat cough swab culture at the screening visit.<br><br>          -  Able to comply with all protocol requirements.<br><br>          -  Clinically stable in the opinion of the investigator.<br><br>          -  Use of an effective means of contraception in females of childbearing potential.<br><br>          -  Provide written informed consent, Health Authority Portability and Accountability Act<br>             (HIPAA) authorization (where applicable), and assent (as appropriate) prior to the<br>             performance of any study-related procedure.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum culture or deep-throat cough swab (or BAL) culture yielding<br>             Burkholderia cepacia (B cepacia), a type of bacteria, within 2 years prior to<br>             screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  Coughing up more than 60 cc of blood from the respiratory tract at any time within 30<br>             days prior to study drug administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  Females who are pregnant (positive pregnancy test), lactating, or are planning to<br>             become pregnant during the study.<br><br>          -  History of hearing loss or chronic ringing in the ears deemed clinically significant<br>             by the investigator.<br><br>          -  Use of systemic or inhaled antipseudomonal antibiotics within 28 days prior to study<br>             drug administration.<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>          -  Use of any investigational treatment within 28 days prior to study drug<br>             administration.<br><br>          -  Initiation of treatment with chronic macrolide therapy, dornase alpha treatment or<br>             inhaled corticosteroids within 28 days prior to study drug administration (patients<br>             may be taking these therapies at the time of enrollment, but they must have initiated<br>             treatment more than 28 days prior to study drug administration).<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Confirmed diagnosis of cystic fibrosis<br><br>          -  Male and female patients at least 6 years of age at the time of screening.<br><br>          -  Forced expiratory volume in one second (FEV1) at screening must be at least 25% and<br>             less than or equal to 75% of normal predicted values for age, sex, and height based on<br>             Knudson criteria.<br><br>          -  Pseudomonas aeruginosa, a type of bacteria, must be present in a sputum/deep-throat<br>             cough swab culture (or bronchoalveolar lavage [BAL]) within 6 months prior to<br>             screening and in the sputum/ deep-throat cough swab culture at the screening visit.<br><br>          -  Able to comply with all protocol requirements.<br><br>          -  Clinically stable in the opinion of the investigator.<br><br>          -  Use of an effective means of contraception in females of childbearing potential.<br><br>          -  Provide written informed consent, Health Authority Portability and Accountability Act<br>             (HIPAA) authorization (where applicable), and assent (as appropriate) prior to the<br>             performance of any study-related procedure.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum culture or deep-throat cough swab (or BAL) culture yielding<br>             Burkholderia cepacia (B cepacia), a type of bacteria, within 2 years prior to<br>             screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  Coughing up more than 60 cc of blood from the respiratory tract at any time within 30<br>             days prior to study drug administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  Females who are pregnant (positive pregnancy test), lactating, or are planning to<br>             become pregnant during the study.<br><br>          -  History of hearing loss or chronic ringing in the ears deemed clinically significant<br>             by the investigator.<br><br>          -  Use of systemic or inhaled antipseudomonal antibiotics within 28 days prior to study<br>             drug administration.<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>          -  Use of any investigational treatment within 28 days prior to study drug<br>             administration.<br><br>          -  Initiation of treatment with chronic macrolide therapy, dornase alpha treatment or<br>             inhaled corticosteroids within 28 days prior to study drug administration (patients<br>             may be taking these therapies at the time of enrollment, but they must have initiated<br>             treatment more than 28 days prior to study drug administration).<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Confirmed diagnosis of cystic fibrosis<br><br>          -  Male and female patients at least 6 years of age at the time of screening.<br><br>          -  Forced expiratory volume in one second (FEV1) at screening must be at least 25% and<br>             less than or equal to 75% of normal predicted values for age, sex, and height based on<br>             Knudson criteria.<br><br>          -  Pseudomonas aeruginosa, a type of bacteria, must be present in a sputum/deep-throat<br>             cough swab culture (or bronchoalveolar lavage [BAL]) within 6 months prior to<br>             screening and in the sputum/ deep-throat cough swab culture at the screening visit.<br><br>          -  Able to comply with all protocol requirements.<br><br>          -  Clinically stable in the opinion of the investigator.<br><br>          -  Use of an effective means of contraception in females of childbearing potential.<br><br>          -  Provide written informed consent, Health Authority Portability and Accountability Act<br>             (HIPAA) authorization (where applicable), and assent (as appropriate) prior to the<br>             performance of any study-related procedure.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum culture or deep-throat cough swab (or BAL) culture yielding<br>             Burkholderia cepacia (B cepacia), a type of bacteria, within 2 years prior to<br>             screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  Coughing up more than 60 cc of blood from the respiratory tract at any time within 30<br>             days prior to study drug administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  Females who are pregnant (positive pregnancy test), lactating, or are planning to<br>             become pregnant during the study.<br><br>          -  History of hearing loss or chronic ringing in the ears deemed clinically significant<br>             by the investigator.<br><br>          -  Use of systemic or inhaled antipseudomonal antibiotics within 28 days prior to study<br>             drug administration.<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>          -  Use of any investigational treatment within 28 days prior to study drug<br>             administration.<br><br>          -  Initiation of treatment with chronic macrolide therapy, dornase alpha treatment or<br>             inhaled corticosteroids within 28 days prior to study drug administration (patients<br>             may be taking these therapies at the time of enrollment, but they must have initiated<br>             treatment more than 28 days prior to study drug administration).<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>      ;<br>        Inclusion Criteria:<br><br>          -  Confirmed diagnosis of cystic fibrosis<br><br>          -  Male and female patients at least 6 years of age at the time of screening.<br><br>          -  Forced expiratory volume in one second (FEV1) at screening must be at least 25% and<br>             less than or equal to 75% of normal predicted values for age, sex, and height based on<br>             Knudson criteria.<br><br>          -  Pseudomonas aeruginosa, a type of bacteria, must be present in a sputum/deep-throat<br>             cough swab culture (or bronchoalveolar lavage [BAL]) within 6 months prior to<br>             screening and in the sputum/ deep-throat cough swab culture at the screening visit.<br><br>          -  Able to comply with all protocol requirements.<br><br>          -  Clinically stable in the opinion of the investigator.<br><br>          -  Use of an effective means of contraception in females of childbearing potential.<br><br>          -  Provide written informed consent, Health Authority Portability and Accountability Act<br>             (HIPAA) authorization (where applicable), and assent (as appropriate) prior to the<br>             performance of any study-related procedure.<br><br>        Exclusion Criteria:<br><br>          -  History of sputum culture or deep-throat cough swab (or BAL) culture yielding<br>             Burkholderia cepacia (B cepacia), a type of bacteria, within 2 years prior to<br>             screening and/or sputum culture yielding B cepacia at screening.<br><br>          -  Coughing up more than 60 cc of blood from the respiratory tract at any time within 30<br>             days prior to study drug administration.<br><br>          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.<br><br>          -  Females who are pregnant (positive pregnancy test), lactating, or are planning to<br>             become pregnant during the study.<br><br>          -  History of hearing loss or chronic ringing in the ears deemed clinically significant<br>             by the investigator.<br><br>          -  Use of systemic or inhaled antipseudomonal antibiotics within 28 days prior to study<br>             drug administration.<br><br>          -  Use of loop diuretics within 7 days prior to study drug administration.<br><br>          -  Use of any investigational treatment within 28 days prior to study drug<br>             administration.<br><br>          -  Initiation of treatment with chronic macrolide therapy, dornase alpha treatment or<br>             inhaled corticosteroids within 28 days prior to study drug administration (patients<br>             may be taking these therapies at the time of enrollment, but they must have initiated<br>             treatment more than 28 days prior to study drug administration).<br><br>        Other protocol-defined inclusion/exclusion criteria may apply<br>